Polianta Ltd’s Ginkgo Bioworks DNA Stock Holding History

Polianta Ltd’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-18,308	Closed	-$973K	–	77
2023 Q1	$973K	Buy	18,308 +9,515	+108%	+$603K	0.45%	64
2022 Q4	$594K	Buy	+8,793	New	+$809K	0.44%	63

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Polianta Ltd's DNA Position: Q2 2023 in Review

Polianta Ltd sold out of Ginkgo Bioworks (DNA) in Q2 2023, closing a stake of 18,308 shares — an estimated $973K sold.

Polianta Ltd first reported a position in DNA in Q4 2022 and held it in 2 quarters. The position peaked at $973K in Q1 2023. 315 funds tracked by Wall St. Rank hold DNA as of Q2 2023.

Polianta Ltd reported no remaining Ginkgo Bioworks position as of Q2 2023 after selling out during the quarter.
Polianta Ltd sold 18,308 Ginkgo Bioworks shares in Q2 2023, an estimated $973K.
Polianta Ltd first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 2 quarters.
Polianta Ltd's Ginkgo Bioworks position peaked at $973K in Q1 2023.
315 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2023.

Based on Polianta Ltd's 13F filing for Q2 2023, filed 19 Jul 2023.